Group 1 - Company Genscript Biotech (01952) saw a significant stock increase of over 6%, reaching HKD 54.45 with a trading volume of HKD 142 million [1] - The company announced the successful enrollment of the first patient in its global multicenter Phase I clinical trial for the universal on-demand cancer therapeutic vaccine EVM14 at NEXT Oncology Virginia in the United States on October 14 [1] - This clinical trial progress follows the approval of the Investigational New Drug (IND) application for EVM14 by both the U.S. FDA and China's NMPA, marking a significant milestone for the company [1] Group 2 - The development of EVM14 addresses critical clinical pain points in the treatment of squamous cell carcinoma, a condition with a large patient population and significant unmet medical needs due to unsatisfactory results from existing standard treatments [2] - EVM14, as a universal on-demand vaccine, offers advantages such as no HLA screening requirement, on-demand supply, lower production costs, and applicability to multiple tumor types, indicating a broad application potential in cancer treatment [2] - The mRNA cancer vaccine market is projected to reach USD 40.651 billion under neutral scenarios, with universal vaccines expected to have a penetration rate significantly exceeding that of personalized products due to cost advantages [2] - EVM14 is positioned to lead in clinical development amidst intense industry competition due to its differentiated advantages [2]
港股异动 | 云顶新耀(01952)早盘涨超6% EVM14直击鳞癌治疗临床痛点 实现临床开发进程领跑